EGR2 is a human zinc finger encoding gene whose expression is induced with fos-like kinetics by diverse mitogens in several cell types. Since Its cDNA sequence predicts a protein which contains zinc finger motifs, EGR2 may play a transcriptional regulatory role in cellular proliferation. The present study was undertaken to: 1) examine the genomic organization and 5' flanking sequence of EGR2 so as to identify upstream regulatory elements; 2) test whether these elements are functional In gel shift assays and by transient expression; and 3) examine whether pathways other than protein kinase C lead to serum induction of EGR2, and if they do, ask whether the different pathways converge on a serum response element. The EGR2 gene spans 4.3 kb and has one intron. The translation initiation site is located within the first exon. The transcription start site of EGR2 was determined by S1 nuclease and primer extension analysis and a TATA box was identified 28 bp upstream. Two putative serum response elements, designated CArG-1 and CArG-2 were identified in the 5' flanking sequence. By deletion analyses and mutagenesis, serum and PMA responsiveness of the cloned EGR2 promoter region was traced to the CArG-1 region in transient CAT assays performed in NIH 3T3 cells. Both protein kinase C dependent and independent pathways were found to converge on the CArG-1 box to induce the expression of EGR2.
INTRODUCTION
To understand the mechanisms by which growth factors modulate cell growth, it is necessary to define the complex series of events that ensue following mitogen-receptor binding Amongst these events are the rapid generation of second messengers in the cytosol and plasma membrane. In turn, a set of 'immediate-early' genes are activated, whose induction does not require new protein synthesis (1, 2) . An important subset of these genes encode transcriptional factors. These include: c-fos (3), fra-1 (4) , and fos B (5), 3 distinct genes (members of the EGR family) designated Egr-1 (6, 7, 8, 9) , EGR2 (10, 11) , and EGR3 (manuscript in preparation), all of which encode proteins with Cys 2 -His2 zinc finger motifs; a member of the steroid and thyroid hormone receptor family (12, 13) ; and c-jun (14, 15, 16, 17) and its closely related genes (18) . The importance of these genes is that by virtue of their structure and induction kinetics, they are likely to play broad roles as 'third messengers' by coupling early biochemical processes to long-term changes in gene expression required to modulate cell growth Furthermore, these gene products also participate as parts of a regulatory cascade in other cellular processes such as in differentiation and cellular depolarization (3, 9) . A major challenge ahead is to define the mechanisms by which specific intracellular second messengers affect expression of one or more members of this subgroup of 'immediate-early' genes and to identify target genes and/or proteins with which products of these genes interact.
Our laboratory is focusing on these questions in the context of the EGR family of genes. Egr-1 displays c-fos like induction kinetics following mitogen stimulation in a broad range of cell types including B (19) and T cells (unpublished data), epithelial cells of renal and liver origin and in fibroblasts (20) . Egr-1 expression is also modulated during neuronal and cardiac differentiation and following cellular depolarization (9) , as well as during EC cell differentiation (unpublished data), following renal hypertrophy, as well as in renal ischemia and liver regeneration (2, unpublished data). We (21) and others (6) have recently published approximately 1 kb of 5' flanking sequence of Egr-1. This region has a variety of putative elements which might confer promoter responsiveness to cAMP, TPA, and serum. We have recently found that CArG elements (sequences of the form CC(A/T) 6 GG) present in this region are crucial in serum induction, and its subsequent down-regulation (Cao et al. and Gius et al., submitted). In an attempt to identify other early growth response genes encoding zinc finger structures, low stringency hybridization with an Egr-1 finger region probe was used to screen a serum plus cycloheximide stimulated fibroblast cDNA library. To date, two novel clones have been identified (designated EGR2 and EGR3). All have zinc fingers very similar to those of Egr-1, but dissimilarity exists elsewhere in the deduced amino acid sequence (7,11, unpublished data) . Furthermore, the
• To whom correspondence should be addressed levels of EGR2 mRNA are elevated following growth stimulation in fibroblasts as well as in lymphocytes (11) , suggesting that, like Egr-1, the expression of EGR2 is not restricted to one cell type. However, unlike Egr-1, EGR2 expression is not induced by nerve growth factor in the rat PC 12 pheochromocytoma cell line (11) . It also shows a strikingly different developmental profile (22) . This paper: 1) presents the intron-exon structure and nucleotide sequence of the flanking region of EGR2 and the identification of two putative serum response elements designated CArG-1 and CArG-2; 2) provides evidence that CArG-1 confers serum as well as PMA responsiveness to the cloned promoter of EGR2, 3) suggests that the CArG-1 and CArG-2 boxes are modulated by the same serum response factor that regulates the CArG/SRE box of c-fos; and 4) demonstrates that in addition to a protein kinase C (PKC) dependent pathway, non-protein kinase C pathways also mediate the serum responsiveness of EGR2 through the CArG-1 box.
MATERIALS AND METHODS

Genomic libraries and isolation of human EGR2 genomic clones.
To obtain EGR2 genomic clones, we screened a WI-38 human fibroblast genomic XFix library (Stratagene, La Jolla, California) and a human placenta! EMBL-3 library kindly provided by Dr. P-labeled 2 kb Zap2 EGR2 cDNA fragment (11) containing the three zinc finger motifs and flanking 5' and 3' sequences ( Fig. 1) . Membranes {GeneScreenPlus, NEN-DuPont) were hybridized for 16 hours at 55°C in 1 % SDS, 10% dextran sulfate and 1 M NaCl. The filters were washed to a final stringency of 55°C in 0.4xSSC (lxSSC = 0.15 M sodium chloride/0.015 M sodium citrate pH 7). Autoradiographs were prepared by exposing the filters for 18 hours at -70°C with an intensifying screen.
Southern blotting and hybridization. All blots used
GeneScreenPlus membranes (NEN-DuPont) and were hybridized at 65°C in 1 % SDS, 10% dextran sulfate and 1 M NaCl. Filters were washed to a final stringency of 65 °C in 0.2xSSC.
DNA sequencing.
Various DNA fragments were subcloned into the polylinker region of either pUC13 or pUC18 and sequenced using Klenow or E. coli T7 polymerase (Pharmacia) according to the dideoxynucleotide chain-termination method (23) .
57 nuclease assay. From plasmid pVA2 (Fig. 3) , an 800 bp PvuII-PvuII fragment was isolated, treated with alkaline phosphatase, and end-labeled. It was then annealed at 85-90°C for 10 minutes to 10 ng of total cellular RNA prepared from unstimulated human 303 fibroblast cells (provided by Dr J. R. Smith, Baylor College of Medicine) and from serum and cycloheximide stimulated 303 cells. Subsequently, hybridization was done for 18 hours in a reaction volume of 30 /il at 50°C in the presence of 60% formamide, 0.4 M NaCl, 0.05 M PIPES and 0.83 mM EDTA. Hybrids were treated with 1 unit of SI nuclease for 1.5 hours at 37°C in a final volume of 300 /xl. The reaction products were extracted with phenol/chloroform, precipitated with 0.3 M sodium acetate pH 4.8, and 2.5 volumes of ethanol, and electrophoresed next to sequencing reaction products used as markers on a 6% polyacrylamide gel containing 8 M urea. The influence of serum stimulation on promoter activity was examined by maintaining the transfected cells for 40 hours in 0.5% FCS followed by 3 hours of growth in DMEM supplemented with 10% FCS. The effect of PMA on promoter activity was examined by addition of 50 nM PMA for 5 hours to the serum-starved cells. In experiments aimed at studying the effect of serum and PMA on PKC deficient cells, transfected cells were cultivated for 40 hours in DMEM/0.5% FCS in the presence of 1 /tM PMA, and depletion of PKC was confirmed by the subsequent loss of PMA inducibility. Cell extracts were prepared and CAT assays were performed as described (24) .
Deletion constructs, and site directed mutagenesis. The EGR2-CAT construct (plasmid pCAT16) was made by deleting about 280 bp of sequence upstream from the PvuII site of the 1.3 kb PvuII-Pvun fragment (VA4) and placing the resulting fragment upstream of the CAT coding sequences as follows. Plasmid pVA4, which contained the EGR2 genomic 1.3 kb PvuIIPvuII fragment cloned into the Smal site of plasmid pUC13, was linearized by digestion with Sad (a unique site in pUC13) and 295 bp from the Sad site were deleted using Bal 31 nuclease. The two ends of the resulting fragment were flushed using Klenow and subsequently digested with Xbal (site in pUC13). The fragment was then cloned into the Xbal-Smal sites of a CATpoly vector constructed by ligating a polylinker sequence into the BglTI site of CAT3M (24) . Plasmid pCAT20 was constructed from pCAT16 by deleting the region between -832 and -201 by cutting with Xbal and Smal, flushing with Klenow, and ligating.
In order to examine the role of the CArG-1 box in serum and PMA inducibility of the cloned EGR2 promoter, two constructs pCAT40, containing an unaltered CArG-1 box, and pCAT50 containing a 'G' to 'T' transversion in the CArG-1 box, were utilized. Plasmid pCAT40 was constructed by using PCR to synthesize a 189 bp fragment (Fig. 2 nt. -73 to +116 containing the CArG-1 box sequence of the EGR2 promoter) by polymerase chain reaction. This fragment was subcloned into the Smal site of the CAT-poly vector in the appropriate orientation. The strategy for construction of pCAT50 was similar to that for pCAT40, except that the synthetic 5' primer used for PCR contained CArG-1 box with the 'G' at position -61 altered to a T .
Gel mobility shift assays. Nuclear extracts were prepared as described (Cao et al, submitted). A 21 bp probe containing the CArG-1 region of EGR2 was constructed by annealing synthetic ohgonucleotides 5'-AGTCCATATATGGGCAGC-GAC-3' and 5'-GTCGCTGCCCATATATGGACT-3' and end-labeling. The unlabeled 21 bp CArG-1 fragment was also used in competition binding experiments. A 36 bp Sau 3A-EcoRI fragment (positions -377 to -342) containing the CArG-2 box was used in competition binding assays. Plasmid p31O-XB5 which contains a 25 bp fragment of the c-fos SRE (CATGAGGATGTCCATA-TTAGGACATCTG) and p310-MU which contains a mutant SRE (CTGACAGGATGTGGATATTACCACATCTG) were gifts from B. H. Cochran. Both plasmids were cut with Pvull and the 300 bp fragments which contained the normal or mutant SREs were isolated and also used as unlabeled competitors. Binding reaction mixtures contained 3 /tg of pUC18 DNA which had been digested with Sau 3A, 2 ng of poly (dl-dC), 5 to 20 /tg nuclear extract, and 1 ng of labeled probe. The binding buffer consisted of 20 mM HEPES, 20% glycerol, 100 mM KC1, 0.2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol and 300 /tg/ml bovine serum albumin. The reaction mixtures were incubated at room temperature for 30 minutes and electrophoresed on 4% polyacrylamide gels, which were dried and autoradiographed.
Northern blot analyses. RNA was prepared by the acidguanidinium thiocyanate-phenol-chloroform extraction technique (25) , electrophoresed on formaldehyde-agarose gel, and blotted onto nitrocellulose (Schleicher and Schuell) in the presence of 20xSSC. Prehybridization and hybridization was performed at 50°C using a buffer consisting of 1X Denhardt's solution, 0.1 % SDS, 10% dextran sulfate, 4xSSC and 5 mM Tris-HCl. Blots were washed at 50°C with 2xSSC, and autoradiographed for 1 week with an intensifying screen at -70°C.
RESULTS
The EGR2 gene has one intron and two exons. Three genomic clones, WI-38.V1, WI-38.V2, WI-38.V3, from the WI-38 library, and one clone, CWP1 from the placental library hybridized to the EGR2 cDNA Zap 2 (11) . To further confirm the authenticity of these clones, Southern blots of various restriction digests were probed with several EGR2 cDNA fragments (Rsa450, p36O, and p80), located as shown (Fig. 1) . The autoradiographs suggested that WI-38.V2 and WI-38.V3, were identical clones but distinct from WI-38.V1 and CWP1 (data not shown). The different EGR2 clones contained colinear AACTTBTTTG CTACITTTAT TTCTSTISAT TTITTTTTCT TCET6T6T3T GGT661T6TT TTTAAGTGI6 6JA6G6CAAAA GGAG^TACCA PE2 +249 + 338 TCCCA66CTC ABTCCMCCC UttCtAftAA C66CTTTTCT GACACTCCAG G7AK5A66G AGTTG6STC! CCAGGTIGT6 CSAGBAGCAA PE1 +339 PvuII ATGATGACC6 CCAAGGCCGT A6ACAAAATC CCA6TAACTC TCA6TGGTTT T6T6CACCAB CI6 restriction enzyme fragments, and a composite restriction map WI-38.V3 into the Smal site of pUC13 and the EcoRI-Kpnl sites (Fig. 1) 5' flanking sequence of the human EGR2 gene shows several consensus regulatory elements. Plasmid pVA4 was employed to obtain the flanking sequence as presented in Fig. 2 . The transcription start site was mapped by SI nuclease analysis as follows. Plasmid pVA2 (900 bp Smal-Smal fragment of EGR2 cloned in pUC13) was digested with PvuEI, and an 800 bp PvuIIPvuII fragment was obtained by utilizing a PvuII site of pUC13 and the PvuII site in the EGR2 genomic portion of the clone (see Fig. 3 ) This fragment was end-labeled and hybridized to RNA prepared from serum plus cycloheximide treated human 303 fibroblasts cells (Fig. 3 , left panel, lane A) or from untreated 303 cells (Fig. 3, left panel, lane B) . The size of the SI nuclease resistant DNA (Fig. 3 , left panel, lane A, shown by thick arrow) indicated that the transcription start site was located approximately 400 bp upstream of the PvuII site. To precisely define the start site location, primer extension analysis was utilized (Fig. 3 , right panel). Using two primers spaced 42 bp apart (PE1 and PE2 shown in Fig. 2 ) extension products on total RNA from serum plus cycloheximide stimulated cells were obtained These fragment sizes (271 and 229 bases) predicted a start site in agreement with the SI analysis data. A second shorter product (Fig. 3 , right panel, arrow) noted with the PE1 primer was not present when hybridization was earned out at a higher temperature (data not shown).
A number of regulatory elements were identified in the 5' upstream region of the VA4 sequence. A putative TATA box (ATAAATA) was identified 28 bp upstream of the transcription start site (nt + 1 in Fig. 2) . Two putative CArG boxes, designated CArG-1 (positions -70 to -61) and CArG-2 (positions -369 to -360) were identified (Fig. 2) . Other putative sequences including two Spl binding sites (GGGCGG, or in the opposite orientation CCGCCC), three API binding sites (27, 28) , and two cAMP responsive elements ([T/G][T/A]-CGTCA) (29) were also noted in the 5' flanking sequence (Fig. 2) .
Serum responsive activity in the 5 'flanking region. To determine whether the EGR2 genomic sequences located 5' of the transcription start site contained promoter activity that was serum inducible, plasmid pCAT16 was tested in a transient expression assay. Plasmid pCAT16 was constructed by placing the EGR2 5' sequence (nt -832 to +116), containing CArG-1 and CArG-2 boxes as well as other putative regulatory elements, upstream of the bacterial chloramphenicol acetyl transferase gene. CAT activity was induced in pCAT16 transfected cells following stimulation with 10% fetal calf serum (Fig. 4, lane B) , whereas cells maintained in 0.5% serum following pCAT16 transfection showed relatively low CAT (Fig. 4, lane A) and from 303 cells that had been stimulated with 10% serum in presence of 10 /ig/ml cycloheximide for 3 hours (lane A). A major -400 bp protected fragment (thick arrow) was seen only in lane A An 800 bp fragment resulting from reanneahng of the two strands of the probe (thin arrow) was seen in both lanes A and B. The restriction sites PvuII (P), Smal (S), and Xbal (X), transcription start site ((*), and translation initiation codon (ATG) are indicated Primer extension products are shown in the right panel Primers (PE1 and PE2 shown in Fig 2) were hybridized at 40°C to RNA from serum plus cycloheximide stimulated 303 cells. Extension products were analyzed on a 7.5% polyacrylamide-8 M urea gel The arrow in the right panel is a shorter extension product which was not detected when hybridization was earned out at a higher temperature (data not shown). Sequencing reactions from a known template were co-run to size the extended fragments 2) were contained within this EGR2 5' sequence. CAT activity in extracts from transfected cells that had been starved for serum, l e. grown in 0.5% serum containing medium (A), and from cells following serum stimulation (B) was determined using '*Cchloramphenicol and the acetylated products were separated following chromatography that 832 bp of 5' upstream sequence is sufficient to confer serum inducibility.
5' sequence containing CArG-1 is sufficient to confer serum responsiveness to the EGR2 promoter. The 5' sequence of EGR2
contains two CArG boxes designated CArG-1 and CArG-2 (see Fig. 2 ). In order to analyze the functional properties of each CArG box, three constructs, pCAT20 and pCAT40 containing only CArG-1, and pCAT50 containing a mutated CArG-1 element were tested for serum responsiveness in transient expression assays. Data is presented as part of Fig. 5 (see CAT activity data on normal (PKC + ) cells). Deletion of CArG-2 did not decrease the serum responsiveness of pCAT20 compared to that of pCAT16 indicating that CArG-1 was sufficient for serum inducibility. This observation was confirmed by the finding that alteration of CArG-1 in plasmid pCAT50 resulted in complete loss of serum responsiveness.
Serum responsiveness has been attributed to the posttranslational modification of a DNA binding protein, serum response factor (SRF), which binds to the SRE region in the 5' Fig. 5 . Effect of deletions and CArG box mutation on serum and PMA responsiveness of the cloned EGR2 promoter Cells were transfected with the different constructs (pCAT16, pCAT20, pCAT40, or pCAT50). Plasmid pCAT16 contained both CArG-1 and CArG-2 elements, whereas pCAT20 and pCAT40 contained only CArG-1, and pCATSO contained mutant CArG-1 sequence One set of cells was grown in presence of 0 5 % serum plus PMA (1 /tM) for 40 hours to deplete PKC, while a second set was grown in 0 5% serum without PMA Cells were then induced with serum, PMA, or left untreated (none), as indicated CAT activity in the extracts was determined using l4C-chloramphenicol and the acetylated products were separated by chromatography The acetylation reactions were deliberately incubated for extended penods of time so as to allow detectable conversion with extracts from cells transfected with pCATSO (PKC" = protein kinase C depleted cells, PKC + = 'normaT cells) sequence of the c-fos promoter and activates transcription (30, 31) . The inner core of the SRE is a CArG box and since we have shown that the CArG-1 sequence in EGR2 is serum responsive, we examined whether this element interacted with nuclear proteins. In gel mobility shift assays, the end-labeled 21 bp CArG-1 fragment migrated as a discrete band in the absence of nuclear extract (Fig. 6A, lane 1; Fig. 6B, lane 1) , but in the presence of extract a single shifted band (Fig. 6A, lane 2; Fig.  6B , lanes 2-4) was evident. The specificity of this interaction was tested by addition of a 10-fold (Fig. 6A, lane 3) , 60-fold (Fig. 6A, lane 4) and 120-fold ( We further examined whether CArG-2 and the c-fos SRE interfered with binding of nuclear factors to CArG-1, and found that binding reactions containing unlabeled CArG-2 (Fig. 6A , . Gel mobility shift of CArG-1 due to specific binding of nuclear factors Binding reactions containing 1 ng of 32 P end-labeled CArG-1 probe and either no extract or 10 ng (unless otherwise specified) of extract were electrophoresed on 4% acrylamide gels For examining competition binding, molar excess of unlabeled CArG fragments were included in the reaction mixtures. Dried gels were exposed overnight at -70°C with an intensifying screen. A lane 1 probe alone, 2 probe plus extract and no competition, 3 -5 competition with CArG-1, 6-8. competition with c-fos SRE, 9-11 competition with CArG-2, 12 -14' competition with c-fos SRE mutant [Unlabeled competitor DNA was in 10-fold molar excess (A lanes 3, 6, 9, and 12), 60-fold molar excess (A lanes 4; 7, 10, and 13), or 120-fold molar excess (A. lanes 5, 8, 11, and 14) over probe DNA ] B lane 1 probe alone, 2. probe plus 4 ng extract and no competition, 3 probe plus 10 ng extract and no competition, 4. probe plus 20 ng extract and no competition, 5 probe and 4 ng extract and competition with 60-fold molar excess of CArG-1, 6-8 probe plus 4 fig extract and competition with CArG-1 mutant at 10, 60, and 120-fold molar excess respectively lanes 9-11) or the c-fos SRE (Fig. 6A, lanes 6-8) abolished labeled CArG-1-protein interactions at 60-fold and 120-fold molar excess (Fig. 6A, lanes 10, 11 and 7, 8) . The mutant SRE of cfos, on the other hand, did not compete with binding of labeled CArG-1 (Fig. 6A, lanes 12-14) . These data suggest that the same nuclear factor, most likely the SRF, binds predominantly to CArG-1, CArG-2, and the SRE of c-fos
The CArG-1 element confers both serum and PMA responsiveness. Besides serum, other mitogenic stimuli such as PMA can induce EGR2 in human fibroblasts and lymphocytes (11) . PMA activates the protein kinase C pathway, and affects transcription of genes containing a PMA responsive element, i.e. the AP-1 binding site. Three putative AP-1 binding sites were identified in the 5' region of EGR2. We, therefore, asked whether these elements mediate PMA responsiveness of the cloned EGR2 promoter. Transient expression studies indicated that CAT activity was inducible in pCAT16, which contained the three putative AP-1 binding elements. However, pCAT20 in which the three AP-1 binding elements were deleted retained PMA responsiveness (Fig. 5) suggesting that the AP-1 binding elements were not essential for PMA inducible transcription. Plasmid pCAT40 contains one putative cAMP binding site and the CArG-1 box. Of these two elements, CArG-1 was specifically examined for PMA responsiveness because recent studies (32) in which the SRE of c-fos was mutated, had revealed that it contributes responsiveness to both serum and PMA. Our construct, pCAT50, retains sequences in the 5' region of EGR2 intact except for CArG-1, which was altered by site directed mutagenesis without affecting the distance between the response elements and the cap site. This plasmid had lost the ability to confer PMA responsiveness (Fig. 5) . These data imply that the CArG-1 sequence of EGR2 is crucial for responsiveness to both serum and PMA.
Serum induces EGR2 in protein kinase C deficient cells. Serum contains a mixture of growth factors, which utilize both PKC dependent and independent second messenger systems for signal transduction. We therefore examined whether serum could activate EGR2 by non-protein kinase C pathways. NIH 3T3 cells were grown for 40 hours in the presence of 0.5% serum or high concentrations of PMA (1 /iM) and 0.5% serum, and following induction with PMA (50 nM) or 10% serum for different periods of time, total RNA was extracted from the cells. The RNA was electrophoresed, transferred to nitrocellulose and probed witĥ P-labeled p80 fragment of EGR2 cDNA (Fig. 1) . Uninduced PKC+ cells (Fig. 7, lane 8 ) expressed low levels of EGR2. However, following treatment with PMA (50 nM) or 10% serum, 1 2 3 4 5 6 7 8 9 10 11 12 13 14 PKC" PKC (Fig. 7 , lanes 9 and 12) and the message levels then dropped at 3 hours (lanes 10 and 13) and 5 hours (Fig. 7, lanes 11 and 14) . Inactivation of the protein kinase C pathway in these cells was confirmed by the inability of PMA, that was subsequently added, to induce EGR2 (Fig. 7, lanes 2, 3 and 4) . The protein kinase C deficient cells, however, retained the ability to induce EGR2 expression following serum stimulation (Fig. 7, lane 5) , implying that nonprotein kinase C dependent pathways are also involved in EGR2 induction.
The EGR2 CArG-1 element responds to PKC dependent and independent pathways. We have demonstrated earlier that, in transient expression assays, the CArG-1 sequence of EGR2 is essential for PMA induction, a mechanism which is known to involve activation of the protein kinase C pathway. When cells transfected with pCAT16, pCAT20, or pCAT40 were made protein kinase C deficient and then treated with serum, they retained serum responsiveness (Fig. 5) . In contrast, pCAT50 transfected cells, when rendered protein kinase C deficient by 40 hours of PMA treatment, lost serum responsiveness in the transient assays. Taken together, these data imply that protein kinase C-dependent as well as protein kinase C-independent pathways operate through the CArG-1 box in order to effect EGR2 transcription.
DISCUSSION
We have presented the genomic organization and about 1 kb of 5' flanking sequence of human EGR2, a mitogen inducible gene which encodes a protein containing three Cys2-His2 zinc finger motifs. We have also shown that the cloned promoter of EGR2 is adequate to provide serum and PMA responsiveness to a heterologous gene. A single CArG box in the 5' flanking region was found to confer both serum and PMA inducibility. This CArG box was the target for both PKC dependent and PKC independent pathways that were induced following serum stimulation of N1H 3T3 cells. These data on EGR2 can now be compared to corresponding information on the c-fos protooncogene, as well to the 5' flanking region of Egr-J.
Genomic organization. Egr-1 and EGR2 are similarly organized in that they both contain two exons and one intron. The translation initiation site of both genes is located within the first exon. The second exon in each case includes three zinc finger motifs with no introns located between the fingers or just outside of the finger domain. Data on a genomic clone for the mouse homologue of EGR2 termed Krox-20 (33) has been reported. Krox-20 contains two introns and three exons. The organization of the EGR2 and Krox-20 genes is quite different from that of TFIIIA where the first six fingers are located on separate exons whereas the last three are not (34) . Two alternative transcripts of the Krox-20 gene were detected in mouse cells (33) . Our SI nuclease and primer extension data indicate the presence of a single transcript for EGR2.
5' flanking sequence. Egr-1, EGR2
, and c-fos are all mitogen inducible genes in a variety of cell types. In the case of c-fos, this effect is mediated by 22 bp element termed serum response element (SRE) (30) . The inner core of 10 nucleotides (CC followed by six A + T's followed by GG) has been referred to as a CArG element and has been found in the X. laevis cytoskeletal actin (35) and human cardiac actin promoters (36) The Egr-1 upstream sequence contains six such elements (6, 21) . (In addition to the five indicated in our paper (21) , there is another one at position -83). It is of interest that EGR2 mRNA, which is induced by serum to peak levels comparable to those of c-fos but five-to-ten fold less than those seen for Egr-1, has only two such elements. The difference in the number of elements is reflected in our EGR2 CAT expression data when compared with that of Egr-1 (Cao et al., submitted). The CArG elements as well as the other putative regulatory elements underscored in Fig. 2 are conserved in the mouse Krox-20 sequence. Deletion analysis of the 5' flanking region of EGR2 revealed that the CArG-1 element was sufficient for serum responsiveness. Mutagenesis of this CArG-1 element completely abolished serum responsiveness of the cloned EGR2 promoter, thereby indicating that this element is critical for serum responsiveness.
EGR2 expression is also inducible by PMA in human peripheral blood lymphocytes (11) and in mouse NIH 3T3 cells (present study). Previous studies have suggested that the effect of PMA is mediated by binding of a fos-jun heterodimer to a cis element of the form [C/G]TGACT[C/A]A (27, 28, (37) (38) (39) (40) (41) . However, the deletion construct pCAT20, in which the region containing all the putative AP-1 binding sites was eliminated, still responded to PMA, indicating that the AP-1 binding elements were unessential for PMA responsiveness. We then asked whether the CArG element contained within the sequence of pCAT20 conferred PMA responsiveness, because the SRE element of cfos was recently shown to confer PMA responsiveness as well. Indeed, construct pCAT50, in which the CArG-1 box was mutagenized, failed to respond to PMA, indicating that the CArG-1 box of EGR2 dictates PMA responsiveness, in addition to serum responsiveness. Furthermore, our data indicates that extended dyad symmetry (present in the c-fos SRE but not surrounding the CArG-1 box of EGR2) is not a prerequisite for serum and PMA responsiveness.
Multiple pathways converge on CArG-1 box. Serum is a complex mixture of growth factors that activate several distinct intracellular signalling pathways. Through mechanisms yet to be defined, it activates a protein termed serum response factor (SRF) which subsequently binds to the SRE of c-fos to induce expression of the gene. The gel mobility shift data from the present study suggested that the SRF might also be binding the CArG-1 box of EGR2. PMA which mainly activates a PKC pathway was found to activate EGR2 expression through the CArG-1 box. We, therefore, asked whether non-PKC pathways also induce EGR2 expression, and if so, whether they operate through the CArG-1 box or other sequences Northern analysis of PKC depleted cells revealed that serum could still induce EGR2 expression. Functional studies of the cloned promoter indicated that mutagenesis of the CArG-1 box completely abolished EGR2 inducibility with serum as well as PMA in PKC+ and PKC depleted cells. Taken together, these data indicate that the EGR2 promoter is activated by both PKC + and PKC~ pathways, all converging on the CArG-1 element.
